Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO

被引：0

作者：

Conca, V. ^{[1
,2
]}

Antoniotti, C. ^{[1
,2
]}

Bergamo, F. ^{[3
]}

Pietrantonio, F. ^{[4
]}

Rossini, D. ^{[1
,2
]}

Scartozzi, M. ^{[5
,6
]}

Perissinotto, E. ^{[7
,8
]}

Leone, A. ^{[4
]}

Pusceddu, V. ^{[5
,6
]}

Borelli, B. ^{[1
,2
,3
]}

Cavanna, L. ^{[9
]}

Latiano, T. ^{[10
]}

Santini, D. ^{[11
]}

Masi, G. ^{[12
]}

Salvatore, L. ^{[13
]}

Frassineti, G. ^{[14
]}

Leone, F. ^{[15
]}

Tamberi, S. ^{[16
]}

Boni, L. ^{[17
]}

Cremolini, C. ^{[1
,2
]}

机构：

[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[3] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[5] Univ Hosp, Med Oncol Unit, Monserrato, Italy

[6] Univ Cagliari, Monserrato, Italy

[7] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[8] Veneto Inst Oncol IOV IRCCS, Med Oncol 1, Padua, Italy

[9] Gen Hosp, Med Oncol Unit, Piacenza, Italy

[10] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy

[11] Sapienza Univ Roma, Policlin Umberto 1, Med Oncol A, Rome, Italy

[12] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Unit Med Oncol, Pisa, Italy

[13] Univ Cattolica Sacro Cuore, Comprehens Canc Ctr, Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol Med, Rome, Italy

[14] Ist Romagnolo Studio Tumori IRST Dino Amadori IRC, Meldola, Italy

[15] ASL BI, Dept Oncol, Osped Infermi Biella, Biella, Italy

[16] AUSL Romagna, UOC Oncol Ravenna, Ravenna, Italy

[17] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SO-27

引用

页码：S173 / S173

页数：1

共 50 条

[1] Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
Conca, Veronica
Antoniotti, Carlotta
Bergamo, Francesca
Pietrantonio, Filippo
Rossini, Daniele
Scartozzi, Mario
Perissinotto, Eleonora
Leone, Alberto Giovanni
Valeria, Pusceddu
Borelli, Beatrice
Cavanna, Luigi
Latiano, Tiziana Pia
Santini, Daniele
Masi, Gianluca
Salvatore, Lisa
Frassineti, Luca
Leone, Francesco
Tamberi, Stefano
Boni, Luca
Cremolini, Chiara
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.
Sunakawa, Yu
Shiozawa, Manabu
Watanabe, Takanori
Ota, Hirofumi
Yasui, Hisateru
Yabuno, Taichi
Tei, Mitsuyoshi
Kochi, Mitsugu
Manaka, Dai
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Tsuji, Akihito
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 120 - 120
[3] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
Antoniotti, Carlotta
Cremolini, Chiara
Loupakis, Fotios
Bergamo, Francesca
Grande, Roberta
Tonini, Giuseppe
Garattini, Silvio Ken
Masi, Gianluca
Battaglin, Francesca
Lucchesi, Sara
Salvatore, Lisa
Corsi, Domenico C.
Di Fabio, Francesca
Banzi, Maria
Sensi, Elisa
Tomcikova, Daniela
Fontanini, Gabriell
Zagonel, Vittorina
Boni, Luca
Falcone, Alfredo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
Cremolini, Chiara
Antoniotti, Carlotta
Lonardi, Sara
Aprile, Giuseppe
Bergamo, Francesca
Masi, Gianluca
Grande, Roberta
Tonini, Giuseppe
Mescoli, Claudia
Cardellino, Giovanni Gerardo
Coltelli, Luigi
Salvatore, Lisa
Corsi, Domenico Cristiano
Lupi, Cristiana
Gemma, Donatello
Ronzoni, Monica
Dell'Aquila, Emanuela
Marmorino, Federica
Di Fabio, Francesca
Mancini, Maria Laura
Marcucci, Lorenzo
Fontanini, Gabriella
Zagonel, Vittorina
Boni, Luca
Falcone, Alfredo
[J]. JAMA ONCOLOGY, 2018, 4 (04) : 529 - 536
[5] Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
Sunakawa, Y.
Shiozawa, M.
Watanabe, T.
Ota, H.
Yasui, H.
Kochi, M.
Manaka, D.
Ohori, H.
Yamaguchi, T.
Kyogoku, T.
Sagawa, T.
Kubota, Y.
Masuishi, T.
Kotaka, M.
Sekikawa, T.
Shimada, K.
Nakamura, M.
Takeuchi, M.
Ichikawa, W.
Fujii, M.
Tsuji, A.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S172 - S172
[6] Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer
Boige, Valerie
Blons, Helene
Francois, Eric
Ben Abdelghani, Meher
Phelip, Jean-Marc
Le Brun-Ly, Valerie
Mineur, Laurent
Galais, Marie Pierre
Villing, Anne-Laure
Hautefeuille, Vincent
Miglianico, Laurent
De La Fouchardiere, Christelle
Genet, Dominique
Levasseur, Nadia
Levache, Charles-Briac
Penel, Nicolas
Mitry, Emmanuel
Jacquot, Stephane
Aparicio, Thomas
Brument, Emilie
Gourgou, Sophie
Castan, Florence
Bouche, Olivier
[J]. JAMA NETWORK OPEN, 2023, 6 (09) : e2333533
[7] Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
Cremolini, Chiara
Loupakis, Fotios
Salvatore, Lisa
Lonardi, Sara
Battaglin, Francesca
Gamucci, Teresa
Grande, Roberta
Di Fabio, Francesca
Liimpe, Fabiola Lorena Rojas
Ferrari, Laura
Casagrande, Mariaelena
Lucchesi, Sara
Tonini, Giuseppe
Banzi, Maria
Valsuani, Chiara
Corsi, Domenico C.
Fontanini, Gabriella
Tomcikova, Daniela
Boni, Luca
Falcone, Alfredo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO
Cremolini, Chiara
Rossini, Daniele
Lonardi, Sara
Antoniotti, Carlotta
Pietrantonio, Filippo
Marmorino, Federica
Antonuzzo, Lorenzo
Boccaccino, Alessandra
Randon, Giovanni
Giommoni, Elisa
Pozzo, Carmelo
Moretto, Roberto
De Grandis, Maria Caterina
Viola, Massimo Giuseppe
Passardi, Alessandro
Buonadonna, Angela
Formica, Vincenzo
Aprile, Giuseppe
Boni, Luca
Masi, Gianluca
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[9] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial
Li, Y.
Wang, D.
Ren, C.
Li, S-S.
Fong, W. Pat
Wu, X.
Xiao, J.
Yuan, Y.
Li, B-K.
Ding, P-R.
Wang, Z.
Wang, F.
Pan, Z.
Chen, G.
Wang, X-Z.
Wang, L-Y.
Chen, T.
Liu, T.
Yuan, Y.
Xu, R-H.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S413 - S414
[10] Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO
Rossini, D.
Antoniotti, C.
Lonardi, S.
Pietrantonio, F.
Marmorino, F.
Antonuzzo, L.
Boccaccino, A.
Randon, G.
Giommoni, E.
Pozzo, C.
Moretto, R.
De Grandis, M.
Viola, M.
Passardi, A.
Borelli, B.
Buonadonna, A.
Masi, G.
Formica, V.
Aprile, G.
Boni, L.
Cremolini, C.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S381 - S381

← 1 2 3 4 5 →